AbbVie has announced a $1.4 billion agreement with the company developing the Alzheimer’s drug ALIA-1758. This acquisition is aimed at enhancing AbbVie’s neuroscience portfolio, particularly in Alzheimer’s disease treatments.
ALIA-1758 is an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody designed to cross the blood-brain barrier using Aliada Therapeutics’ proprietary Modular Delivery (MODEL™) platform. This platform targets specific receptors to facilitate the delivery of therapeutic antibodies and genetic medicines into the brain. Currently, ALIA-1758 is in a Phase 1 clinical trial to assess its safety and tolerability in healthy participants.
The transaction is expected to close by the end of 2024, pending regulatory approvals and standard closing conditions.
